{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:12:14Z","timestamp":1791807134809,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed\/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-na\u00efve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-na\u00efve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P &amp;lt; .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013747","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T13:52:34Z","timestamp":1722606754000},"page":"6139-6147","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-4498","authenticated-orcid":false,"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"1Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-5152","authenticated-orcid":false,"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam E.","family":"Kopmar","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"6Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone E.","family":"Dekker","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"35Division of Hematology-Oncology, Oregon Health Science, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"7Division of Hematology & Oncology, University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-4434","authenticated-orcid":false,"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[{"name":"10Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Valtis","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[{"name":"9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Miller","sequence":"additional","affiliation":[{"name":"9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sutherland","sequence":"additional","affiliation":[{"name":"9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-1755","authenticated-orcid":false,"given":"Kaitlyn C.","family":"Dykes","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-215X","authenticated-orcid":false,"given":"Evan","family":"Chen","sequence":"additional","affiliation":[{"name":"14Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Zambrano","sequence":"additional","affiliation":[{"name":"15Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7721-3747","authenticated-orcid":false,"given":"Danielle","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"16Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mercadal","sequence":"additional","affiliation":[{"name":"17Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"18Department of Hematology and Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Tracy","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"20Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kubiak","sequence":"additional","affiliation":[{"name":"16Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"21Department of Hematology and Oncology, Oncology Hematology Care, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[{"name":"22Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Battiwalla","sequence":"additional","affiliation":[{"name":"22Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[{"name":"23Department of Lymphoma, Colorado Blood Cancer Institute, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz A.","family":"Malik","sequence":"additional","affiliation":[{"name":"24Center for Blood Cancer and Oncology, Texas Transplant Institute, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[{"name":"25Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, Midland, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"26Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"27Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9598-6467","authenticated-orcid":false,"given":"Abdullah","family":"Ladha","sequence":"additional","affiliation":[{"name":"28Department of Hematology, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Stefan","sequence":"additional","affiliation":[{"name":"6Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Guzowski","sequence":"additional","affiliation":[{"name":"29Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus T.","family":"Hoeg","sequence":"additional","affiliation":[{"name":"30Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[{"name":"31Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-5790","authenticated-orcid":false,"given":"Jozal","family":"Moore","sequence":"additional","affiliation":[{"name":"32Division of Hematology\/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-0623","authenticated-orcid":false,"given":"Matthew","family":"Connor","sequence":"additional","affiliation":[{"name":"33Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"32Division of Hematology\/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[{"name":"10Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua","family":"Sasine","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem M.","family":"Solh","sequence":"additional","affiliation":[{"name":"29Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-8955","authenticated-orcid":false,"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"17Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[{"name":"16Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Koura","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Veeraputhiran","sequence":"additional","affiliation":[{"name":"34Department of Hematology and Oncology, University of Arkansas Medical Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Blunk","sequence":"additional","affiliation":[{"name":"22Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspian","family":"Oliai","sequence":"additional","affiliation":[{"name":"7Division of Hematology & Oncology, University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica T.","family":"Leonard","sequence":"additional","affiliation":[{"name":"35Division of Hematology-Oncology, Oregon Health Science, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[{"name":"33Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"14Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Galal","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"1Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"4","key":"2024121016205955600_bib1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.26853","article-title":"Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"issue":"14","key":"2024121016205955600_bib2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"2024121016205955600_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024121016205955600_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.33298","article-title":"Long-term survival of patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"127","author":"Topp","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"2024121016205955600_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"2024121016205955600_bib6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10299","key":"2024121016205955600_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2024121016205955600_bib8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024121016205955600_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2024121016205955600_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121016205955600_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2023-177693","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry","volume":"142","author":"Bezerra","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121016205955600_bib12","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2023-182531","article-title":"Brexucabtagene autoleucel in adults with relapsed\/refractory B-cell ALL: outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult ALL (ROCCA)","volume":"142","author":"Roloff","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121016205955600_bib13","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood-2023-180575","article-title":"Efficacy and tolerance of brexucabtagene autoleucel in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: a Graall study from the Descar-T registry","volume":"142","author":"Rabian","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024121016205955600_bib14","doi-asserted-by":"crossref","first-page":"e007118","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2024121016205955600_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"2024121016205955600_bib16","doi-asserted-by":"crossref","first-page":"311.e1","DOI":"10.1016\/j.jtct.2023.02.012","article-title":"The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL","volume":"29","author":"Rubinstein","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"2024121016205955600_bib17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"35","author":"Winick","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024121016205955600_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024121016205955600_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024121016205955600_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jtct.2023.01.017","article-title":"Post-transplantation sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation inotuzumab","volume":"29","author":"Agrawal","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2024121016205955600_bib21","first-page":"1385","article-title":"Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease","volume":"109","author":"Kayser","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6139\/2344972\/blooda_adv-2024-013747-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6139\/2344972\/blooda_adv-2024-013747-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:51:46Z","timestamp":1733831506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/6139\/517265\/Impact-of-prior-inotuzumab-ozogamicin-treatment-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":21,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013747","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}